These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
488 related articles for article (PubMed ID: 33320838)
1. Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. Ferrere G; Tidjani Alou M; Liu P; Goubet AG; Fidelle M; Kepp O; Durand S; Iebba V; Fluckiger A; Daillère R; Thelemaque C; Grajeda-Iglesias C; Alves Costa Silva C; Aprahamian F; Lefevre D; Zhao L; Ryffel B; Colomba E; Arnedos M; Drubay D; Rauber C; Raoult D; Asnicar F; Spector T; Segata N; Derosa L; Kroemer G; Zitvogel L JCI Insight; 2021 Jan; 6(2):. PubMed ID: 33320838 [TBL] [Abstract][Full Text] [Related]
2. Ketogenic diet enhances the anti-cancer effects of PD-L1 blockade in renal cell carcinoma. Richard J; Beauvillain C; Benoit M; Barth M; Aubert C; Rolley C; Bellal S; Bourreau J; Ferragu M; Lebdai S; Chevrollier A; Henrion D; Procaccio V; Bigot P Front Endocrinol (Lausanne); 2024; 15():1344891. PubMed ID: 38846490 [TBL] [Abstract][Full Text] [Related]
3. Ketogenic Diet Alters the Epigenetic and Immune Landscape of Prostate Cancer to Overcome Resistance to Immune Checkpoint Blockade Therapy. Murphy S; Rahmy S; Gan D; Liu G; Zhu Y; Manyak M; Duong L; He J; Schofield JH; Schafer ZT; Li J; Lu X; Lu X Cancer Res; 2024 May; 84(10):1597-1612. PubMed ID: 38588411 [TBL] [Abstract][Full Text] [Related]
4. Activation of G protein-coupled receptors by ketone bodies: Clinical implication of the ketogenic diet in metabolic disorders. Spigoni V; Cinquegrani G; Iannozzi NT; Frigeri G; Maggiolo G; Maggi M; Parello V; Dei Cas A Front Endocrinol (Lausanne); 2022; 13():972890. PubMed ID: 36339405 [TBL] [Abstract][Full Text] [Related]
5. On the nutritional and therapeutic effects of ketone body D-β-hydroxybutyrate. Yao A; Li Z; Lyu J; Yu L; Wei S; Xue L; Wang H; Chen GQ Appl Microbiol Biotechnol; 2021 Aug; 105(16-17):6229-6243. PubMed ID: 34415393 [TBL] [Abstract][Full Text] [Related]
6. Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. Maurer GD; Brucker DP; Bähr O; Harter PN; Hattingen E; Walenta S; Mueller-Klieser W; Steinbach JP; Rieger J BMC Cancer; 2011 Jul; 11():315. PubMed ID: 21791085 [TBL] [Abstract][Full Text] [Related]
8. A ketogenic diet increases transport and oxidation of ketone bodies in RG2 and 9L gliomas without affecting tumor growth. De Feyter HM; Behar KL; Rao JU; Madden-Hennessey K; Ip KL; Hyder F; Drewes LR; Geschwind JF; de Graaf RA; Rothman DL Neuro Oncol; 2016 Aug; 18(8):1079-87. PubMed ID: 27142056 [TBL] [Abstract][Full Text] [Related]
9. Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. Dai X; Bu X; Gao Y; Guo J; Hu J; Jiang C; Zhang Z; Xu K; Duan J; He S; Zhang J; Wan L; Liu T; Zhou X; Hung MC; Freeman GJ; Wei W Mol Cell; 2021 Jun; 81(11):2317-2331.e6. PubMed ID: 33909988 [TBL] [Abstract][Full Text] [Related]
10. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
12. Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4 Beavis PA; Henderson MA; Giuffrida L; Davenport AJ; Petley EV; House IG; Lai J; Sek K; Milenkovski N; John LB; Mardiana S; Slaney CY; Trapani JA; Loi S; Kershaw MH; Haynes NM; Darcy PK Cancer Immunol Res; 2018 Sep; 6(9):1069-1081. PubMed ID: 30018045 [TBL] [Abstract][Full Text] [Related]
13. Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8 Hutmacher C; Gonzalo Núñez N; Liuzzi AR; Becher B; Neri D Cancer Immunol Res; 2019 Apr; 7(4):572-583. PubMed ID: 30782667 [TBL] [Abstract][Full Text] [Related]
14. Ketogenic diet administration to mice after a high-fat-diet regimen promotes weight loss, glycemic normalization and induces adaptations of ketogenic pathways in liver and kidney. Nasser S; Solé T; Vega N; Thomas T; Balcerczyk A; Strigini M; Pirola L Mol Metab; 2022 Nov; 65():101578. PubMed ID: 35995402 [TBL] [Abstract][Full Text] [Related]
15. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840 [TBL] [Abstract][Full Text] [Related]
16. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098 [TBL] [Abstract][Full Text] [Related]
17. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity. Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075 [TBL] [Abstract][Full Text] [Related]
19. Ketogenic Effects of Multiple Doses of a Medium Chain Triglycerides Enriched Ketogenic Formula in Healthy Men under the Ketogenic Diet: A Randomized, Double-Blinded, Placebo-Controlled Study. Nakamura K; Hagihara K; Nagai N; Egashira R; Takeuchi M; Nakano M; Saito H; Moriguchi M; Tonari S; Watanabe S; Miyake A; Ashida K Nutrients; 2022 Mar; 14(6):. PubMed ID: 35334856 [TBL] [Abstract][Full Text] [Related]
20. Low ketolytic enzyme levels in tumors predict ketogenic diet responses in cancer cell lines in vitro and in vivo. Zhang J; Jia PP; Liu QL; Cong MH; Gao Y; Shi HP; Yu WN; Miao MY J Lipid Res; 2018 Apr; 59(4):625-634. PubMed ID: 29414764 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]